Valued at USD 25.52 billion in 2024, the legal marijuana market is projected to reach USD 31.71 billion in 2025 and USD 233.33 billion by 2034, growing at a CAGR of 24.8% during the forecast period 2025–2034. Key players include ABcann Medicinals, Inc.; Aphria Inc.; Aurora Cannabis; Canopy Growth Corporation; Cronos Group; GW Pharmaceuticals, Plc.; Lexaria Corporation; Maricann Inc.; Organigram Holdings Inc.; and Tilray. Increasing medical research and clinical studies are boosting growth opportunities.

Medical Cannabis Dominates Application Revenue

The medical segment dominated with a 69.12% revenue share in 2024 due to expanding acceptance of medical cannabis in treatments for chronic pain, cancer-related symptoms, neurological disorders, and anxiety. Regulatory approvals for medical cannabis programs in multiple regions and growing clinical evidence have fueled adoption among patients and healthcare providers. The segment also benefits from higher product standardization and dosing control. In February 2025, the University at Buffalo partnered with Pure Jamaican/Seven-10 Pharmaceuticals and DENT to study therapeutic cannabinoid uses across Jamaica, the U.S., and Brazil.

Chronic Pain and Cancer Care

The chronic pain segment held a 26.10% market share in 2024, driven by cannabis's recognized analgesic properties and its ability to provide relief without the severe side effects of long-term opioid use. The cancer segment is projected to register a 40.2% CAGR during 2025–2034, owing to growing use in managing appetite loss, pain, and fatigue. An October 2024 CDC report states that chronic diseases account for USD 4.9 trillion in annual U.S. healthcare expenditures, with approximately 60% of Americans having at least one chronic condition. Patients with arthritis, neuropathy, and musculoskeletal disorders increasingly turn to cannabis-based products, and multiple administration forms, such as smoking, edibles, topicals, and oils, enhance patient compliance.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/legal-marijuana-market

Product and Compound Segments

Buds held a 64.1% share in 2024 owing to consumer familiarity and accessibility. Oils & concentrates are expected to register a 39.3% CAGR, supported by demand for high-potency, discreet products with precise dosing and extraction advances that improve purity and consistency. By compound, THC-dominant products accounted for 54.44% of 2024 revenue, sought for recreational enjoyment and uses such as appetite stimulation and pain relief. Cannabidiol (CBD)-dominant products are forecast to grow at the highest CAGR of 39.4%, driven by demand for non-psychoactive wellness products in skincare, beverages, supplements, and pet care. Buds are preferred for both medical and recreational use.

Legal Marijuana Market Regional Analysis

North America held a 69.00% global share in 2024, supported by established regulatory frameworks and cannabis infrastructure, with the U.S. accounting for 94.48% of the regional market. Europe held 18.84% of global revenue, attributed to steady expansion of medical cannabis programs and investment in research and development, with Germany driven by a robust prescription-based framework. Asia Pacific is projected to register a 37.6% CAGR from 2025 to 2034 amid shifting regulatory attitudes, rising healthcare expenditure, and growing interest in cannabis-based medical treatments. India's market is also expanding, supported by research into traditional and medicinal applications.

Competitive Landscape and Developments

Major companies use mergers and acquisitions to strengthen regional footprints, while technological advances in extraction and delivery methods enhance product offerings. In May 2025, Curaleaf International expanded into Australia's medical cannabis market, launching four flower strains through local distributor Canngea. In August 2025, Metrc and BioTrack formed BT Government to handle government cannabis tracking. Small and medium-sized businesses are innovating with CBD-dominant products and craft cultivation, creating new revenue opportunities.

Growth Drivers and Market Challenges

Key drivers include increasing medical research and clinical studies, favorable government initiatives in the U.S. and Europe, and the growing prevalence of chronic diseases. Ongoing scientific investigations are expanding knowledge of cannabis efficacy in managing conditions such as chronic pain, epilepsy, and multiple sclerosis, which promotes greater acceptance among healthcare professionals and policymakers and drives product innovation, standardized dosing, and quality assurance. Restraints include strict and fragmented regulations that create compliance hurdles, raising costs and operational complexity, as well as low Legal Marijuana market penetration in developing and underdeveloped countries.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market